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1. INTRODUCTION {#mgg31368-sec-0005}
===============

Colorectal cancer (CRC) is one of the main causes of cancer‐related morbidity and mortality worldwide (Bray et al., [2018](#mgg31368-bib-0010){ref-type="ref"}). In Saudi Arabia, CRC ranked first among males and third in females, accounting for 12.2% of all newly diagnosed cancer cases in 2015. Furthermore, the median age at diagnosis is approximately 10 years younger in Saudi Arabia compared to Western countries (Alrawaji, Alshahrani, Alzahrani, Alomran, & Almadouj, [2018](#mgg31368-bib-0004){ref-type="ref"}; Howlader et al., [2016](#mgg31368-bib-0025){ref-type="ref"}), and a nearly twofold increase in age‐standardized rate of CRC was observed in Saudi Arabia from 1994 to 2015 whereas the incidence of CRC has stabilized or decreased in the West (Al‐Eid, [1994](#mgg31368-bib-0003){ref-type="ref"}; Alrawaji et al., [2018](#mgg31368-bib-0004){ref-type="ref"}). The causes of these disparities are still not fully elucidated, but the differences of genetic features in different populations may play an important role.

Although up to one‐third of CRCs are attributed to heritable genetic factors, only \~5% of all CRCs are known to be caused by well‐defined, inherited germline pathogenic variants in CRC predisposing genes with high penetrance including *MLH1, MSH2, MSH6,* and *PMS2* (MMR genes), *EPCAM* and *MUTYH* (Al‐Tassan et al., [2002](#mgg31368-bib-0005){ref-type="ref"}; Grady, [2003](#mgg31368-bib-0022){ref-type="ref"}; Jasperson, Tuohy, Neklason, & Burt, [2010](#mgg31368-bib-0026){ref-type="ref"}; Lichtenstein et al., [2000](#mgg31368-bib-0030){ref-type="ref"}; Weren et al., [2015](#mgg31368-bib-0047){ref-type="ref"}). The remaining cases are not fully understood. There is a probability that the pathogenic variants in less penetrant genes could be associated with the well‐characterized syndromes. Therefore, a precise understanding of the genetic characteristics of CRC is critical for identifying individuals with high risk to develop CRC, improving cancer prevention and surveillance strategies and developing better diagnostic and therapeutic approaches.

Owing to the advances in sequencing technology, several novel cancer‐related genes have recently been discovered, including *POLE* (OMIM: \*174,762) and *POLD1* (OMIM: \*174,761) genes (Bellido et al., [2016](#mgg31368-bib-0007){ref-type="ref"}; Calva‐Cerqueira et al., [2010](#mgg31368-bib-0012){ref-type="ref"}; Gala et al., [2014](#mgg31368-bib-0020){ref-type="ref"}; Houlston et al., [1998](#mgg31368-bib-0024){ref-type="ref"}; Spier et al., [2015](#mgg31368-bib-0043){ref-type="ref"}). *POLE* and *POLD1* encode the catalytic subunit of the polymerase enzyme complexes Epsilon (ε) and Delta (δ), respectively, and play a key role in DNA replication and repair (Nick McElhinny, Gordenin, Stith, Burgers, & Kunkel, [2008](#mgg31368-bib-0032){ref-type="ref"}; Pursell, Isoz, Lundstrom, Johansson, & Kunkel, [2007](#mgg31368-bib-0034){ref-type="ref"}). Formal estimates of penetrance suggest that pathogenic variants in POLD1 are associated with high penetrance for the disease (Bellido et al., [2016](#mgg31368-bib-0007){ref-type="ref"}; Buchanan et al., [2018](#mgg31368-bib-0011){ref-type="ref"}; Palles et al., [2013](#mgg31368-bib-0033){ref-type="ref"}; Spier et al., [2015](#mgg31368-bib-0043){ref-type="ref"}). Subsequent screenings revealed that exonuclease domain pathogenic variants were present in 0.1%--0.8% of CRCs with family history of CRC, multiple adenomas or early‐onset in Western populations (Chubb et al., [2015](#mgg31368-bib-0015){ref-type="ref"}; Elsayed et al., [2015](#mgg31368-bib-0019){ref-type="ref"}; Palles et al., [2013](#mgg31368-bib-0033){ref-type="ref"}; Valle et al., [2014](#mgg31368-bib-0044){ref-type="ref"}), whereas relatively higher frequency (2.9%) of pathogenic variants in *POLE* and *POLD1* genes was seen in a CRC cohort of Chinese population (Dong et al., [2019](#mgg31368-bib-0017){ref-type="ref"}). Furthermore, the exonuclease domain pathogenic variants of these two genes were shown to be associated with hyper‐mutation phenotype and significant response to immunotherapy using immune checkpoints inhibitor (Bourdais et al., [2017](#mgg31368-bib-0009){ref-type="ref"}; Ciardiello et al., [2019](#mgg31368-bib-0016){ref-type="ref"}; Gong, Wang, Lee, Chu, & Fakih, [2017](#mgg31368-bib-0021){ref-type="ref"}; Palles et al., [2013](#mgg31368-bib-0033){ref-type="ref"}). However, the underlying causes of CRC in genetically unexplained cases and their clinico‐pathological characteristics in CRCs from the Middle East are still unknown.

The aim of this study was to explore the spectrum, frequency, and phenotype of *POLE* and *POLD1* exonuclease domain pathogenic variants in a large CRC cohort from the Middle East. This may increase the knowledge of mechanisms underlying CRC and assist in the implementation of therapeutic and/or preventive strategies in Middle Eastern population.

2. MATERIALS AND METHODS {#mgg31368-sec-0006}
========================

2.1. Editorial policies and ethical considerations {#mgg31368-sec-0007}
--------------------------------------------------

This study was approved by Institutional Review Board. Waiver of consent was provided by Research Advisory Council to obtain archival paraffin tissue blocks under project RAC \# 2040 004.

2.2. Sample selection {#mgg31368-sec-0008}
---------------------

One thousand one hundred and thirty‐five CRC archival samples of patients diagnosed at KFSHRC between 1990 and 2015 were included in the present study. Clinico‐pathological details for the cases were collected from medical records, which are summarized in Table [1](#mgg31368-tbl-0001){ref-type="table"}.

###### 

Clinico‐pathological variables for the patient cohort (*n* = 1,135)

  Clinico‐pathological parameter   *n* (%)
  -------------------------------- --------------
  Age                              
  Median                           55.0
  Range(IQR)                       46.4--66.1
  Gender                           
  Male                             599 (52.8)
  Female                           536 (47.2)
  Histological subtype             
  Adenocarcinoma                   1,002 (88.3)
  Mucinous carcinoma               133 (11.7)
  Histological grade               
  Well differentiated              105 (9.3)
  Moderately differentiated        881 (77.6)
  Poorly differentiated            112 (9.9)
  Unknown                          37 (3.2)
  Tumor site                       
  Left                             915 (80.6)
  Right                            206 (18.1)
  Unknown                          14 (1.2)
  TNM stage                        
  I                                153 (13.5)
  II                               357 (31.5)
  III                              452 (39.8)
  IV                               142 (12.5)
  Unknown                          31 (2.7)

Abbreviation: IQR, Inter quartile range.
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2.3. DNA extraction {#mgg31368-sec-0009}
-------------------

DNAs were extracted from CRC non‐tumor formalin‐fixed and paraffin‐embedded (FFPE) tissues utilizing Gentra DNA isolation kit (Gentra) according to manufacturer\'s protocols as elaborated in the previous studies (Abubaker et al., [2008](#mgg31368-bib-0001){ref-type="ref"}; Khoo et al., [1999](#mgg31368-bib-0027){ref-type="ref"}).

2.4. Targeted capture sequencing of germline exonuclease domain variants in *POLE* and *POLD1* genes {#mgg31368-sec-0010}
----------------------------------------------------------------------------------------------------

Capture sequencing of 376 CRC cases was carried out using a capture panel as previously reported (Siraj et al., [2017](#mgg31368-bib-0040){ref-type="ref"}). The concentrations were estimated and DNA samples having A260/A280 ratio from 1.8 to 2.0 were used for library preparation. Random fragmentation of DNA was carried out to prepare the sequencing library, followed by adapter ligation at 5′ and 3′ ends. These fragments were then amplified by PCR and purified after gel electrophoresis. The library was then transferred to a flow cell to generate clusters by attachment to complementary adapters bound to surface of the flow cell. The fragments were amplified into clusters by bridge amplification. The base call data were generated by Illumina\'s Hiseq control, version 3.3.

The base call data (BCL files) were converted into FASTQ format using Illumina\'s bcl2fastq (v2.16). The FASTQ reads were mapped to the human reference genome hg19 by burrows wheeler aligner (BWA; Li & Durbin, [2010](#mgg31368-bib-0028){ref-type="ref"}). The bam files generated by BWA were converted into compressed bam format using Picard‐tools. PCR duplicates were marked and realignment was carried out on the bam files to get high quality variants using genome analysis toolkit (GATK) and Picard‐tools (McKenna et al., [2010](#mgg31368-bib-0031){ref-type="ref"}).

The variants were called using GATK. The variants were annotated with different annotation databases like dbSNP, 1000 genomes, Exome Aggregation Consortium (ExAC), Exome Sequencing Project (ESP6500) and ClinVar and an in‐house database of around 3,000 healthy exomes using ANNOVAR (Wang, Li, & Hakonarson, [2010](#mgg31368-bib-0046){ref-type="ref"}).

Our targeted capture panel uses similar sequencing technology as Liang et al., [2016](#mgg31368-bib-0029){ref-type="ref"} and Beaubier et al., [2019](#mgg31368-bib-0006){ref-type="ref"}. These studies have estimated the sensitivity and specificity of mutation detection by targeted capture sequencing to be \>98% for all types of alterations with expected MAF of \>5% at a sequencing coverage of \>2000X. The depth of coverage for our targeted capture sequencing is \>1500X and being germline mutations where MAF is close to 50%, the specificity and sensitivity will be more than 98%. (Beaubier et al., [2019](#mgg31368-bib-0006){ref-type="ref"}; Liang et al., [2016](#mgg31368-bib-0029){ref-type="ref"}).

2.5. PCR and sanger sequencing to detect germline exonuclease domain variants in *POLE* and *POLD1* genes {#mgg31368-sec-0011}
---------------------------------------------------------------------------------------------------------

Sequencing of whole coding and splicing regions of *POLE* (GenBank: NG_033840.1) and *POLD1* (GenBank: NG_033800.1) exonuclease domain among 759 samples were carried out using Sanger sequencing technology. Additionally, variants detected by Capture sequencing were subsequently validated by Sanger sequencing. Primer 3 online software was utilized to design the primers (available upon request). PCR and Sanger sequencing were carried out as described previously (Siraj et al., [2019](#mgg31368-bib-0041){ref-type="ref"}).

2.6. Assessment of pathogenicity of variants {#mgg31368-sec-0012}
--------------------------------------------

ACMG/AMP 2015 guideline was utilized first for interpretation of sequence variants (Richards et al., [2015](#mgg31368-bib-0037){ref-type="ref"}). All the variants of uncertain significance (VUSs) interpreted by ACMG/AMP 2015 were further analyzed using five in silico pathogenicity prediction tools: PolyPhen‐2 (Adzhubei et al., [2010](#mgg31368-bib-0002){ref-type="ref"}), MutationAssessor (Reva, Antipin, & Sander, [2011](#mgg31368-bib-0036){ref-type="ref"}), SIFT (Vaser, Adusumalli, Leng, Sikic, & Ng, [2016](#mgg31368-bib-0045){ref-type="ref"}), CADD (Rentzsch, Witten, Cooper, Shendure, & Kircher, [2019](#mgg31368-bib-0035){ref-type="ref"}) and Mutation Taster (Schwarz, Cooper, Schuelke, & Seelow, [2014](#mgg31368-bib-0038){ref-type="ref"}). The variants predicted as damaging or possibly damaging by three or more in silico prediction tools were further investigated.

2.7. Tissue microarray construction & Immunohistochemistry {#mgg31368-sec-0013}
----------------------------------------------------------

Tissue microarray (TMA) was utilized for analyses of samples. Construction of TMA was performed as described previously (Siraj et al., [2007](#mgg31368-bib-0039){ref-type="ref"}). Two cores from each case of CRC were arrayed.

Immunohistochemistry (IHC) staining was performed using a standard protocol as described previously (Siraj et al., [2019](#mgg31368-bib-0041){ref-type="ref"}). Staining of slides with omission of the primary antibody served as negative controls. Simultaneous staining of fresh cut slides was performed to reduce the effect of slide aging and to optimize the staining.

For evaluation of IHC staining, intensity (I) and percentage (P) of positively stained tumor cells was assessed for each case as follows: intensity score was assigned ranging from 0 to 3 (I0‐negative; I1‐weak; I2‐moderate; I3‐strong) and percentage of positively stained tumor cells for each intensity score was assigned ranging from 0%--100% (P0--P3). The product of the scores obtained for each intensity and the corresponding percentage of tumor cells stained were added to obtain the final H score (=I1XP1 + I2XP2 + I3XP3), which ranged from 0 to 300. Using X‐tile version 3.6.1 (Camp, Dolled‐Filhart, & Rimm, [2004](#mgg31368-bib-0013){ref-type="ref"}), H score of 70 and 120 was defined as the cutoff for POLE and POLD1, respectively. The cases having score below the cutoff were considered to have low expression and those having score above the cutoff were classified as over expression.

Mismatch repair protein staining and evaluation was done as described previously (Siraj et al., [2015](#mgg31368-bib-0042){ref-type="ref"}).

2.8. Statistical analysis {#mgg31368-sec-0014}
-------------------------

The associations between protein expression and clinico‐pathological variables were performed using contingency table analysis and Chi‐square tests. Kaplan--Meier method was used to generate overall survival curves and Mantel--Cox log‐rank test was used to assess significance. Two‐sided tests were used for statistical analyses with a limit of significance defined as *p *\< .05. The JMP11.0 (SAS Institute, Inc.) software was used for data analyses.

3. RESULTS {#mgg31368-sec-0015}
==========

3.1. Sample characteristics {#mgg31368-sec-0016}
---------------------------

A total of 1,135 CRC cases were included in the study. The median age of the study cohort was 55 years. The majority of the cases was of adenocarcinoma histologic subtype (88.3%), moderately differentiated (77.6%), and left‐sided (80.6%) tumors (Table [1](#mgg31368-tbl-0001){ref-type="table"}).

3.2. Identification of germline exonuclease domain variants in *POLE* and *POLD1* genes {#mgg31368-sec-0017}
---------------------------------------------------------------------------------------

Out of 376 CRC cases sequenced utilizing capture sequencing, three variants, two in *POLE* and one in *POLD1*, were detected and interpreted as of uncertain significance utilizing ACMG/AMP 2015 guideline. Furthermore, five in silico prediction tools were utilized for further analysis. Two variants (c.940T\>G: p.Ser314Ala and c.1370C\>T: p.Thr457Met) in *POLE* were assessed as damaging or possibly damaging, accounting for 0.5% (2/376) of all samples analyzed by Capture sequencing. To increase our cohort, we included another 759 CRC cases sequenced by Sanger sequencing technology. In this cohort, six variants were interpreted as of uncertain significance by ACMG/AMP 2015 guideline, three in *POLE* and three in *POLD1*. Further analysis using pathogenicity prediction tools revealed that three (0.4%, 3/759) were damaging or possibly damaging, two (c.1024C\>T: p.His342Tyr and c.1184G\>A: p.Gly395Glu) in *POLE* and one (c.932G\>G: p.Arg311His) in *POLD1*. Altogether, five variants (0.44%) were classified by ACMG guidelines as variants of uncertain significance, in silico prediction tools in the 1,135 CRC cases identified four variants in *POLE* (0.35%, 4/1,135) and one variant in *POLD1* (0.1%, 1/1,135; Table [2](#mgg31368-tbl-0002){ref-type="table"}) to warrant further investigation.

###### 

Characteristics of five damaging or possibly damaging variants identified in our cohort

  Gene                                             Variant                    ACMG                     PolyPhen‐2          Mutation assessor   SIFT        CADD   Mutation taster   Onset age   Family history   Conserved   Frequency in ExAC
  ------------------------------------------------ -------------------------- ------------------------ ------------------- ------------------- ----------- ------ ----------------- ----------- ---------------- ----------- -------------------
  POLE[^a^](#mgg31368-note-0003){ref-type="fn"}    c.1370C\>T:p.(Thr457Met)   Uncertain significance   Probably damaging   Low                 Tolerated   25.1   Disease causing   52          NA               4/6         ABSENT
  POLE                                             c.940T\>G:p.(Ser314Ala)    Uncertain significance   Benign              Medium              Tolerated   22.1   Disease causing   47          Positive         6/6         0.00008
  POLE                                             c.1024C\>T:p.(His342Tyr)   Uncertain significance   Benign              Low                 Damaging    22.3   Disease causing   47          NA               3/6         Absent
  POLE                                             c.1184G\>A:p.(Gly395Glu)   Uncertain significance   Possibly damaging   Low                 Tolerated   28     Disease causing   50          NA               5/6         0.00009
  POLD1[^b^](#mgg31368-note-0004){ref-type="fn"}   c.932G\>A:p.(Arg311His)    Uncertain significance   Probably damaging   High                Damaging    24.7   Disease causing   90          NA               7/7         Absent

GenBank accession number NG_033840.1

GenBank accession number NG_033800.1

John Wiley & Sons, Ltd

Two heterozygous POLE variants p.(Ser314Ala) and p.(Thr457Met) were detected by capture sequencing. The *POLE* heterozygous variant p.(Ser314Ala) was identified in an early‐onset CRC patient (diagnosed at 47 years of age) with large tubulovillous adenoma. The patient carrying this variant has strong family history of CRC and Familial adenomatous polyposis (FAP; Figure [1](#mgg31368-fig-0001){ref-type="fig"}). Furthermore, this variant is fully conserved and is also identified in population database ExAC at a very low frequency of 0.00008. p.(Thr457Met) in POLE was detected in CRC patient diagnosed at 52 years. This variant was also highly conserved and absent in ExAC. The patients carrying these two variants are not known to carry any germline pathogenic variants in other CRC‐predisposing genes. The variants of p.(His342Tyr) and p.(Gly395Glu) in *POLE* were detected in CRC patients diagnosed at 47 and 50 years, respectively. p.(His342Tyr) variant was highly conserved and absent in ExAC whereas p.(Gly395Glu) was observed at a low frequency of 0.00009 in ExAC (Table [2](#mgg31368-tbl-0002){ref-type="table"}). IHC expression of MMR genes in the cases having these two variants was normal therefore further sequencing analysis was not performed.

![Pedigree of the patient having *POLE* c.940T\>G: p.(Ser314Ala) variant. The indexed patient is indicated by arrow. Circles indicate female; square, male; slash forward, individual deceased; dark square or circle, affected by cancer; CRC indicates colorectal cancer; FAP indicates Familial adenomatous polyposis; PTC indicates Papillary Thyroid cancer; Dx. Age indicates Age at diagnosis](MGG3-8-e1368-g001){#mgg31368-fig-0001}

The *POLD1* variant of p.(Arg311His) was identified by Sanger sequencing in a patient with late onset of CRC (diagnosed at 90 years of age). However, this variant is completely conserved among species and is predicted as damaging or possibly damaging variant by all five prediction tools. Additionally, the p.(Arg311His) variant is absent in ExAC (Table [2](#mgg31368-tbl-0002){ref-type="table"}). This case was also enrolled in another ongoing study in which Sanger sequencing was employed to screen the germline and somatic MMR genes variants. However, the patient does not carry any germline or somatic pathogenic variants in MMR genes (data not shown). Interestingly, the tumor from this patient is deficient MMR (dMMR) as assessed by IHC.

We further sought to explore the possible associations between *POLE*/*POLD1* damaging or possibly damaging variants and clinico‐pathological parameters. However, no significant association was found between *POLE*/*POLD1* disease--causing variants and clinico‐pathological characteristics such as age, gender, grade, stage, histologic subtype, tumor site, and MSI status.

3.3. Protein expression of POLE and POLD1 genes in CRC and their clinico‐pathological associations {#mgg31368-sec-0018}
--------------------------------------------------------------------------------------------------

We further examined the expression of POLE and POLD1 proteins by IHC in 1,135 CRC cases in TMA format. POLE expression was interpretable in 1,071 cases. Low expression of POLE was detected in 38.9% (417/1071) of cases (Figure [2a,b](#mgg31368-fig-0002){ref-type="fig"}) and revealed a significant association with lymph node involvement (*p* = .0184) and grade 3 tumors (*p* = .0139; Table [3](#mgg31368-tbl-0003){ref-type="table"}). POLD1 expression was interpretable in 1,069 cases. Low expression of POLD1 was observed in 51.9% (555/1069) cases (Figure [2c,d](#mgg31368-fig-0002){ref-type="fig"}) and showed significant association with adenocarcinoma histology (*p* = .0164), larger tumor size (T3 and T4 tumors; *p* = .0012), and stage III tumors (*p* = .0341; Table [4](#mgg31368-tbl-0004){ref-type="table"}). However, there was no association between protein expression and these five *POLE*/*POLD1* exonuclease domain variants.

![Tissue microarray based immunohistochemistry analysis of *POLE* and *POLD1* in CRC patients. CRC TMA cores showing overexpression of POLE (a) and POLD1 (c). In contrast, another set of TMA cores showing reduced expression of POLE (B) and POLD1 (e). 20 X/0.70 objective on an Olympus BX 51 microscope. (Olympus America Inc.) with the inset showing a 40 × 0.85 aperture magnified view of the same TMA spot](MGG3-8-e1368-g002){#mgg31368-fig-0002}

###### 

Correlation of POLE IHC expression with clinico‐pathological parameters in colorectal carcinoma

                          Total   Low    High   *p* value                
  ----------------------- ------- ------ ------ ----------- ----- ------ -------
  Total number of cases   1,071          417    38.9        654   61.1   
  Age                                                                    
  ≤50 years               367     34.4   138    37.6        229   62.4   .5421
  \>50 years              701     65.6   277    39.5        424   60.5   
  Sex                                                                    
  Male                    564     52.7   221    39.2        343   60.8   .8602
  Female                  507     47.3   196    38.7        311   61.3   
  Tumor site                                                             
  Left colon              857     80.9   329    38.4        528   61.6   .4037
  Right colon             202     19.1   84     41.6        118   58.4   
  histological type                                                      
  Adenocarcinoma          948     88.8   363    38.3        585   61.7   .2883
  Mucinous carcinoma      120     11.2   52     43.3        68    56.7   
  pT                                                                     
  T1/T2                   198     19.2   71     35.9        127   64.1   .3495
  T3/T4                   834     80.8   329    39.5        505   60.5   
  pN                                                                     
  N0                      508     49.7   178    35.0        330   65.0   .0184
  N1/N2                   514     50.3   217    42.2        297   57.8   
  pM                                                                     
  M0                      916     87.7   357    39.0        559   61.0   .8802
  M1                      128     12.3   49     38.3        79    61.7   
  Tumor stage                                                            
  I                       143     13.8   50     35.0        93    65.0   .2041
  II                      345     33.1   127    36.8        218   63.2   
  III                     425     40.8   183    43.1        242   56.9   
  IV                      128     12.3   49     38.3        79    61.7   
  Differentiation                                                        
  Well                    99      9.5    34     34.3        65    65.7   .0139
  Moderate                842     80.4   319    37.9        523   62.1   
  Poor                    106     10.1   55     51.9        51    48.1   
  MSH2 IHC                                                               
  Positive                942     90.1   361    38.3        581   61.7   .2916
  Negative                103     9.9    45     43.7        58    56.3   
  POLE mutation                                                          
  Yes                     3       0.3    2      66.7        1     33.3   .3315
  No                      1,068   99.7   415    38.9        653   61.1   
  Survival                                                               
  OS 5 years                                    71.9              72.8   .5934
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###### 

Correlation of POLD1 IHC expression with clinico‐pathological parameters in colorectal carcinoma

                          Total   Low    High   p value                
  ----------------------- ------- ------ ------ --------- ----- ------ -------
  Total number of cases   1,069          555    51.9      514   48.1   
  Age                                                                  
  ≤50 years               366     34.3   187    51.1      179   48.9   .6786
  \>50 years              700     65.7   367    52.4      333   47.6   
  Sex                                                                  
  Male                    562     52.6   290    51.6      272   48.4   .8275
  Female                  507     47.4   265    52.3      242   47.7   
  Tumor site                                                           
  Left colon              856     81.0   453    52.9      403   47.1   .1162
  Right colon             201     19.0   94     46.8      107   53.2   
  Histological type                                                    
  Adenocarcinoma          946     88.7   504    53.3      442   46.7   .0164
  Mucinous carcinoma      120     11.3   50     41.7      70    58.3   
  pT                                                                   
  T1/T2                   198     19.2   82     41.4      116   58.6   .0012
  T3/T4                   832     80.8   451    54.2      381   45.8   
  pN                                                                   
  N0                      507     49.7   246    48.5      261   51.5   .0802
  N1/N2                   513     50.3   277    54.0      236   46.0   
  pM                                                                   
  M0                      914     87.7   475    52.0      439   48.0   .6763
  M1                      128     12.3   64     50.0      64    50.0   
  Tumor stage                                                          
  I                       143     13.8   59     41.3      84    58.7   .0341
  II                      344     33.1   182    52.9      162   47.1   
  III                     424     40.8   234    55.2      190   44.8   
  IV                      128     12.3   64     50.0      64    50.0   
  Differentiation                                                      
  Well                    99      9.5    57     57.6      42    42.4   .2026
  Moderate                840     80.4   440    52.4      400   47.6   
  Poor                    106     10.1   48     45.3      58    54.7   
  MSH2 IHC                                                             
  Positive                941     90.2   487    51.7      454   48.3   .8196
  Negative                102     9.8    54     52.9      48    47.1   
  POLD1 mutation                                                       
  Yes                     1       0.1    1      100.0     0     0.0    .2521
  No                      1,068   99.9   554    51.9      514   48.1   
  Survival                                                             
  OS 5 years                                    71.9            73.0   .3640

John Wiley & Sons, Ltd

4. DISCUSSION {#mgg31368-sec-0019}
=============

Although a wealth of knowledge has been acquired, the picture of germline genetic alterations causing CRC is still incomplete. In this study, we examined the germline exonuclease domain variants of *POLE* and *POLD1* genes to identify predisposing variants in a large CRC cohort from the Middle East. We detected four heterozygous damaging or possibly damaging variants in *POLE* and one heterozygous damaging or possibly damaging variant in *POLD1*, accounting for 0.4% of all CRC patients. The frequency of damaging or possibly damaging variants in Middle Eastern CRC was similar to that in Western populations (Chubb et al., [2015](#mgg31368-bib-0015){ref-type="ref"}; Elsayed et al., [2015](#mgg31368-bib-0019){ref-type="ref"}; Palles et al., [2013](#mgg31368-bib-0033){ref-type="ref"}; Valle et al., [2014](#mgg31368-bib-0044){ref-type="ref"}). However, there is insufficient data to assess the functional impact of these genetic variants on the protein; therefore, these variants are classified as a Variant of Uncertain Significance by ACMG. In our cohort, we did not identify any damaging or possibly damaging variants which were frequently detected previously in Western populations, indicating the unique spectrum of germline exonuclease domain variants of *POLE* and *POLD1* in our population.

Our data provide some evidence that POLE p.Ser314Ala is associated with increased risk for CRC. The patient carrying the variant of *POLE* p.(Ser314Ala) had large adenoma and early onset phenotype with strong family history of CRC and FAP, similar to that of previously reported pathogenic *POLE* variant p.(Leu424Val; Palles et al., [2013](#mgg31368-bib-0033){ref-type="ref"}) and resembling Lynch syndrome. Furthermore, absence of other germline pathogenic variants in CRC predisposing genes including *APC*, *MUTYH,* and MMR genes indicates that this variant might be the causative variant of CRC. Moreover this variant is fully conserved between six species and observed in population database at a much lower frequency. These data might indicate the pathogenic effect of this variant. Interestingly one sister of the patient carrying this variant developed papillary thyroid carcinoma (PTC), therefore further analysis is required to investigate whether *POLE* p.(Ser314Ala) variant is driver of PTC. The other three *POLE* variants p.(His342Tyr), p.(Gly395Glu), and p.(Thr457Met) were also found in early onset CRC patients and absent or observed at low frequency in ExAC. All the variants were partially conserved and predicted as pathogenic by three in silico prediction tools. Interestingly, the variant p.(His342Tyr) was previously reported to be present in a hyper‐mutant tumor (Campbell et al., [2017](#mgg31368-bib-0014){ref-type="ref"}). This hyper‐mutation phenotype indicates that p.(His342Tyr) might have strong mutagenic effect. However, due to conservative culture in the Middle East, family history information from the carriers of p.(His342Tyr) and p.(Thr457Met) variants were not available (Bou Khalil, [2013](#mgg31368-bib-0008){ref-type="ref"}; Eldeek et al., [2014](#mgg31368-bib-0018){ref-type="ref"}).

Although the *POLD1* variant of c.932G\>A: p.(Arg311His) was found in a late onset patient, the amino acid Arg is fully conserved between all seven species and is predicted as damaging or possibly damaging by all prediction tools. Furthermore, this variant is absent in ExAC. All these data suggested that this variant may cause loss of function of *POLD1*. In addition, the tumor from this patient is dMMR by IHC assessment. Additional, germline and somatic pathogenic variants of MMR genes by Sanger sequencing were not detected in this patient (data not shown). This result is consistent with previous finding that MSI--H tumor might possess exonuclease domain pathogenic variants in *POLD1* (Haradhvala et al., [2018](#mgg31368-bib-0023){ref-type="ref"}).

In this study, we did not observe association between germline damaging or possibly damaging variants of *POLE* and *POLD1* genes and their protein expression. This result might be partially explained by the fact that *POLE* and *POLD1* somatic exonuclease domain variants were not investigated in current study. Interestingly, a previous study reported that compared to the exonuclease domain region more truncated variants were detected in the region outside of this domain, and more than 30% of *POLE* and *POLD1* truncated variants did not result in high tumor mutation burden (TMB) in the tumors (Campbell et al., [2017](#mgg31368-bib-0014){ref-type="ref"}). In addition, another study also reported that POLE IHC has no predictive value for effect of mutation (Elsayed et al., [2015](#mgg31368-bib-0019){ref-type="ref"}). All these results implied that IHC analysis of these two genes might not be suitable to select the patients for immune checkpoint inhibitor therapy.

To the best of our knowledge, we are the first to report the frequency and clinico‐pathological associations of protein expression in POLE and POLD1 genes in CRCs. POLE and POLD1 low expression was associated with adverse prognostic factors. However, no significant survival outcomes were noted with both biomarkers. Further studies are warranted to validate our findings.

In conclusion, we showed a low frequency of germline damaging or possibly damaging variants in exonuclease domain of *POLE* and *POLD1* in CRC patients from the Middle East. We recommend that screening of *POLE* and *POLD1* exonuclease region should be applied for identification of individuals that are at an increased risk of developing CRC and patients who might be suitable for immunotherapy. Compared to single gene testing next generation sequencing technology provides critical benefits by reduction in cost and time therefore, it is feasible to screen multiple cancer predisposing genes in CRC patients using multi‐gene panels including *POLE* and *POLD1*.
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